SCHEMBL5384029

SCHEMBL5384029

CCOC(=O)C(O)(CC(C)(C)c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.47
POLB P06746 3/20 0.46
MMP8 P22894 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
CHRM2 P08172 3/20 0.42
CHRM1 P11229 3/20 0.42
CHRM3 P20309 3/20 0.42
ALDH1A1 P00352 2/20 0.42
CHRM4 P08173 2/20 0.42
RECQL P46063 1/20 0.42
CHRM5 P08912 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.40
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40
THRB P10828 1/20 0.40
KCNN4 O15554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10745657 0.83 PIN1 (0.53) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL5396329 0.82 POLB (0.60) PIN1POLBMMP8NPSR1ALDH1A1
SCHEMBL13625401 0.81 PIN1 (0.51) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL6690054 0.81 POLB (0.46) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL10745489 0.80 PIN1 (0.50) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL9516972 0.80 PIN1 (0.50) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL14510428 0.80 PIN1 (0.50) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL5807773 0.80 PIN1 (0.57) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL13574069 0.80 PIN1 (0.57) PIN1POLBMMP8NPSR1SMN1; SMN2
SCHEMBL3948530 0.79 CYP2C19 (0.47) ALDH1A1KMT2ATSHRMAPTNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238707-B2 Substituted pentanols, a process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2007-07-03 US disclosed
EP-1673344-A1 1-(QUINOLINE AMINO) AND 1-(ISOQUINOLINE AMINO)-SUBSTITUTED PENTAN-2-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORIES Schering Aktiengesellschaft (DE) 2006-06-28 EP disclosed
US-20050143415-A1 Substituted pentanols, a process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2005-06-30 US disclosed
WO-2005035502-A1 1-(QUINOLINE AMINO) AND 1-(ISOQUINOLINE AMINO)-SUBSTITUTED PENTAN-2-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORIES SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143415-A1 Substituted pentanols, a process for their production and their use as anti-inflammatory agents PTGES, TNF, PTGES2 PIN1 3316/4885POLB 2611/4885MMP8 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.